Signaling pathways downstream to receptor tyrosine kinases: targets for cancer treatment

Abstract

Mammalian cells have the ability to respond to a myriad of diverse extracellular stimuli that modulate cell function. This often involves ligands binding to cell surface receptors and subsequent activation of intracellular signaling pathways. These pathways can lead to changes in gene expression patterns that in turn regulate cell growth, differentiation, migration, and function. One important type of cell surface receptor is the receptor tyrosine kinase (RTK). In response to in response to ligand binding, RTKs dimerize, then trans-phosphorylate each other, leading to activation of downstream pathways. While the signaling proteins in these pathways are important for normal cell growth control, when improperly regulated they can lead to uncontrolled growth and sometimes cancer. For this reason, they are often considered to be good candidates for drug targets for chemotherapeutic drugs. RTKs can activate multiple different signaling pathways. Some of the signaling proteins in these pathways can have crosstalk with other RTK activated pathways, and some of them can be activated by multiple mechanisms in addition to activation by RTKs. While there is a wide array of different signaling proteins and pathways activated by RTKs, in this review we will discuss components of several key pathways including the MAPK pathway, the Her2/Neu pathway, mTOR, and Pak kinases. We provide an overview of the roles for these pathways in cell signaling and discuss how different components of these pathways are being considered as targets for cancer treatment.

Keywords

Receptor tyrosine kinases / signaling pathways / targeted cancer therapeutics / oncogenes / cell signaling

References

[1] Lemmon MA.Cell signaling by receptor tyrosine kinases..Cell2010;141:1117-34 PMCID:PMC2914105

[2] Ghosh S,Yarden Y.Roles for receptor tyrosine kinases in tumor progression and implications for cancer treatment..Adv Cancer Res2020;147:1-57

[3] Du Z.Mechanisms of receptor tyrosine kinase activation in cancer..Mol Cancer2018;17:58 PMCID:PMC5817791

[4] Simanshu DK,McCormick F.RAS proteins and their regulators in human disease..Cell2017;170:17-33 PMCID:PMC5555610

[5] Braicu C,Busuioc C.A comprehensive review on MAPK: a promising therapeutic target in cancer..Cancers2019;11:1618 PMCID:PMC6827047

[6] Whitmarsh AJ.Regulation of gene transcription by mitogen-activated protein kinase signaling pathways..Biochim Biophys Acta2007;1773:1285-98

[7] Chappell WH,Long JM.Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health..Oncotarget2011;2:135-64 PMCID:PMC3260807

[8] Mendoza MC,Blenis J.The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation..Trends Biochem Sci2011;36:320-8 PMCID:PMC3112285

[9] Cargnello M.Activation and function of the MAPKs and their substrates, the MAPK-activated protein kinases..Microbiol Mol Biol Rev2011;75:50-83 PMCID:PMC3063353

[10] Dhillon AS,Rath O.MAP kinase signalling pathways in cancer..Oncogene2007;26:3279-90

[11] McCubrey JA,Chappell WH.Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance..Biochim Biophys Acta2007;1773:1263-84 PMCID:PMC2696318

[12] Santarpia L,El-Naggar AK.Targeting the MAPK-RAS-RAF signaling pathway in cancer therapy..Expert Opin Ther Targets2012;16:103-19 PMCID:PMC3457779

[13] Novotny CJ,McCormick F.Farnesyltransferase-mediated delivery of a covalent inhibitor overcomes alternative prenylation to mislocalize K-Ras..ACS Chem Biol2017;12:1956-62 PMCID:PMC6070134

[14] O’Bryan JP.Pharmacological targeting of RAS: recent success with direct inhibitors..Pharmacol Res2019;139:503-11 PMCID:PMC6360110

[15] Mullard A.Cracking KRAS..Nat Rev Drug Discov2019;18:887-891

[16] Canon J,Saiki AY.The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity..Nature2019;575:217-23

[17] Seton-Rogers S.KRAS-G12C in the crosshairs..Nat Rev Cancer2020;20:3

[18] Muratcioglu S,Freed BC.GTP-dependent K-Ras dimerization..Structure2015;23:1325-35 PMCID:PMC4497850

[19] Ambrogio C,Zhou ZW.KRAS dimerization impacts MEK inhibitor sensitivity and oncogenic activity of mutant KRAS..Cell2018;172:857-68.e15

[20] Durrant DE.Targeting the Raf kinases in human cancer: the Raf dimer dilemma..Br J Cancer2018;118:3-8 PMCID:PMC5765234

[21] Matallanas D,Romano D.Raf family kinases: old dogs have learned new tricks..Genes Cancer2011;2:232-60 PMCID:PMC3128629

[22] Croce L,Magri F,Rotondi M.The multifaceted anti-cancer effects of BRAF-inhibitors..Oncotarget2019;10:6623-40 PMCID:PMC6859927

[23] Ritterhouse LL.BRAF V600E mutation-specific antibody: a review..Semin Diagn Pathol2015;32:400-8

[24] Falchook GS,Infante JR.Activity of the oral MEK inhibitor trametinib in patients with advanced melanoma: a phase 1 dose-escalation trial..Lancet Oncol2012;13:782-9 PMCID:PMC4109286

[25] Rosen LS,Ma WW.A first-in-human phase I study to evaluate the MEK1/2 inhibitor, cobimetinib, administered daily in patients with advanced solid tumors..Invest New Drugs2016;34:604-13 PMCID:PMC6863157

[26] Grimaldi AM,Festino L,Palla M.Novel mechanisms and therapeutic approaches in melanoma: targeting the MAPK pathway..Discov Med2015;19:455-61

[27] Maik-Rachline G,Seger R.Nuclear ERK: mechanism of translocation, substrates, and role in cancer..Int J Mol Sci2019;20:1194 PMCID:PMC6429060

[28] Burotto M,Lee JM.The MAPK pathway across different malignancies: a new perspective..Cancer2014;120:3446-56 PMCID:PMC4221543

[29] Marampon F,Zani BM.Biological rationale for targeting MEK/ERK pathways in anti-cancer therapy and to potentiate tumour responses to radiation..Int J Mol Sci2019;20: PMCID:PMC6567863

[30] Smalley I.ERK inhibition: a new front in the war against MAPK pathway-driven cancers?.Cancer Discov2018;8:140-2

[31] Sullivan RJ,Janku F.First-in-class ERK1/2 inhibitor Ulixertinib (BVD-523) in patients with MAPK mutant advanced solid tumors: results of a phase I dose-escalation and expansion study..Cancer Discov2018;8:184-95

[32] Jaiswal BS,Stawiski EW.ERK mutations and amplification confer resistance to ERK-inhibitor therapy..Clin Cancer Res2018;24:4044-55

[33] Tai W,Cheng K.The role of HER2 in cancer therapy and targeted drug delivery..J Control Release2010;146:264-75 PMCID:PMC2918695

[34] Hsu JL.The role of HER2, EGFR, and other receptor tyrosine kinases in breast cancer..Cancer Metastasis Rev2016;35:575-88 PMCID:PMC5215954

[35] Wee P.Epidermal growth factor receptor cell proliferation signaling pathways..Cancers (Basel)2017;9:52 PMCID:PMC5447962

[36] Irby RB.Role of Src expression and activation in human cancer..Oncogene2000;19:5636-42

[37] Moasser MM.The oncogene HER2: its signaling and transforming functions and its role in human cancer pathogenesis..Oncogene2007;26:6469-87 PMCID:PMC3021475

[38] Guo P,Chen S.Breast cancers with EGFR and HER2 co-amplification favor distant metastasis and poor clinical outcome..Oncol Lett2017;14:6562-70 PMCID:PMC5696709

[39] Iqbal N.Human epidermal growth factor receptor 2 (HER2) in cancers: overexpression and therapeutic implications..Mol Biol Int2014;2014:852748 PMCID:PMC4170925

[40] Belsches-Jablonski AP,Peavy DR,Romney DA.Src family kinases and HER2 interactions in human breast cancer cell growth and survival..Oncogene2001;20:1465-75

[41] Freudenberg JA,Katsumata M,Nagatomo I.The role of HER2 in early breast cancer metastasis and the origins of resistance to HER2-targeted therapies..Exp Mol Pathol2009;87:1-11 PMCID:PMC2735009

[42] Li YM,Wei YK.Upregulation of CXCR4 is essential for HER2-mediated tumor metastasis..Cancer Cell2004;6:459-69

[43] Timms JF,O’Hare MJ.Effects of ErbB-2 overexpression on mitogenic signalling and cell cycle progression in human breast luminal epithelial cells..Oncogene2002;21:6573-86

[44] Siadati S,Nikbakhsh N.Correlation of ER, PR and HER-2/Neu with other prognostic factors in infiltrating ductal carcinoma of breast..Iran J Pathol2015;10:221-6 PMCID:PMC4539777

[45] Linderholm B,Lindh B.Overexpression of c-erbB-2 is related to a higher expression of vascular endothelial growth factor (VEGF) and constitutes an independent prognostic factor in primary node-positive breast cancer after adjuvant systemic treatment..Eur J Cancer2004;40:33-42

[46] van Roy F.The cell-cell adhesion molecule E-cadherin..Cell Mol Life Sci2008;65:3756-88

[47] Schroeder JA,McConnell EJ,Pockaj B.ErbB-beta-catenin complexes are associated with human infiltrating ductal breast and murine mammary tumor virus (MMTV)-Wnt-1 and MMTV-c-Neu transgenic carcinomas..J Biol Chem2002;277:22692-8

[48] Rexer BN.Intrinsic and acquired resistance to HER2-targeted therapies in HER2 gene-amplified breast cancer: mechanisms and clinical implications..Crit Rev Oncog2012;17:1-16 PMCID:PMC3394454

[49] Cuello M,Clark AS.Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2..Cancer Res2001;61:4892-900

[50] Junttila TT,Parsons K.Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941..Cancer Cell2009;15:429-40

[51] Gajria D.HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies..Expert Rev Anticancer Ther2011;11:263-75 PMCID:PMC3092522

[52] Yakes FM,Ritter RA,Seelig S.Herceptin-induced inhibition of phosphatidylinositol-3 kinase and Akt Is required for antibody-mediated effects on p27, cyclin D1, and antitumor action..Cancer Res2002;62:4132-41

[53] Parra-Palau JL,Peg V.Effect of p95HER2/611CTF on the response to trastuzumab and chemotherapy..J Natl Cancer Inst2014;106:dju291 PMCID:PMC4271027

[54] Pohlmann PR,Mernaugh R.Resistance to trastuzumab in breast cancer..Clin Cancer Res2009;15:7479-91 PMCID:PMC3471537

[55] Scaltriti M,Prudkin L.Clinical benefit of lapatinib-based therapy in patients with human epidermal growth factor receptor 2-positive breast tumors coexpressing the truncated p95HER2 receptor..Clin Cancer Res2010;16:2688-95 PMCID:PMC3243489

[56] Collins DM,Kannan S.Preclinical characteristics of the irreversible Pan-HER kinase inhibitor neratinib compared with lapatinib: implications for the treatment of HER2-positive and HER2-mutated breast cancer..Cancers (Basel)2019;11:737 PMCID:PMC6628314

[57] Saura C,Feng YH.Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ≥ 2 HER2-directed regimens: phase III NALA trial..J Clin Oncol2020;38:3138-49 PMCID:PMC7499616

[58] Nagy P,Tanner M.Decreased accessibility and lack of activation of ErbB2 in JIMT-1, a herceptin-resistant, MUC4-expressing breast cancer cell line..Cancer Res2005;65:473-82

[59] Gu S,Ngamcherdtrakul W.Therapeutic siRNA for drug-resistant HER2-positive breast cancer..Oncotarget2016;7:14727-41 PMCID:PMC4924747

[60] Faltus T,Zimmer B.Silencing of the HER2/neu gene by siRNA inhibits proliferation and induces apoptosis in HER2/neu-overexpressing breast cancer cells..Neoplasia2004;6:786-95 PMCID:PMC1531682

[61] Gu S,Reda M,Gray JW.Lack of acquired resistance in HER2-positive breast cancer cells after long-term HER2 siRNA nanoparticle treatment..PLoS One2018;13:e0198141 PMCID:PMC5991725

[62] Ortega MA,Asúnsolo Á,García-Honduvilla N.Signal transduction pathways in breast cancer: the important role of PI3K/Akt/mTOR..J Oncol2020;2020:9258396 PMCID:PMC7085392

[63] Jean S.Classes of phosphoinositide 3-kinases at a glance..J Cell Sci2014;127:923-8 PMCID:PMC3937771

[64] Papa A.The PTEN-PI3K axis in cancer..Biomolecules2019;9:153 PMCID:PMC6523724

[65] Pópulo H,Soares P.The mTOR signalling pathway in human cancer..Int J Mol Sci2012;13:1886-918 PMCID:PMC3291999

[66] Chamcheu JC,Uddin MB.Role and therapeutic targeting of the PI3K/Akt/mTOR signaling pathway in skin cancer: a review of current status and future trends on natural and synthetic agents therapy..Cells2019;8:803 PMCID:PMC6721560

[67] Luo Y,Li G.Weighing in on mTOR Complex 2 signaling: the expanding role in cell metabolism..Oxid Med Cell Longev2018;2018:7838647 PMCID:PMC6232796

[68] Yuan TL.PI3K pathway alterations in cancer: variations on a theme..Oncogene2008;27:5497-510 PMCID:PMC3398461

[69] Tornillo L.An update on molecular genetics of gastrointestinal stromal tumours..J Clin Pathol2006;59:557-63 PMCID:PMC1860404

[70] Carvalho I,Martins A,Schmitt F.Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression..Breast Cancer Res2005;7:R788-95 PMCID:PMC1242156

[71] Samuels Y.Oncogenic mutations of PIK3CA in human cancers..Curr Top Microbiol Immunol2010;347:21-41 PMCID:PMC3164550

[72] Hyman DM,Donoghue MTA.AKT inhibition in solid tumors with AKT1 mutations..J Clin Oncol2017;35:2251-9 PMCID:PMC5501365

[73] Grabiner BC,Birsoy K.A diverse array of cancer-associated MTOR mutations are hyperactivating and can predict rapamycin sensitivity..Cancer Discov2014;4:554-63 PMCID:PMC4012430

[74] Akinleye A,Furqan M,Liu DL.Phosphatidylinositol 3-kinase (PI3K) inhibitors as cancer therapeutics..J Hematol Oncol2013;6:88 PMCID:PMC3843585

[75] Maira SM,Huang A.Identification and characterization of NVP-BKM120, an orally available pan-class I PI3-kinase inhibitor..Mol Cancer Ther2012;11:317-28

[76] Liu N,Bull CO.BAY 80-6946 is a highly selective intravenous PI3K inhibitor with potent p110α and p110δ activities in tumor cell lines and xenograft models..Mol Cancer Ther2013;12:2319-30

[77] Hanker AB,Arteaga CL.Challenges for the clinical development of PI3K inhibitors: strategies to improve their impact in solid tumors..Cancer Discov2019;9:482-91 PMCID:PMC6445714

[78] Yang J,Ma X,Peng Y.Targeting PI3K in cancer: mechanisms and advances in clinical trials..Mol Cancer2019;18:26 PMCID:PMC6379961

[79] Wang X,Meng LH.PI3K isoform-selective inhibitors: next-generation targeted cancer therapies..Acta Pharmacol Sin2015;36:1170-6 PMCID:PMC4648175

[80] Fritsch C,Chatenay-Rivauday C.Characterization of the novel and specific PI3Kα inhibitor NVP-BYL719 and development of the patient stratification strategy for clinical trials..Mol Cancer Ther2014;13:1117-29

[81] Zhou W,Liu M,Wang G.Targeting CXCL12/CXCR4 Axis in tumor immunotherapy..Curr Med Chem2019;26:3026-41 PMCID:PMC5949083

[82] Schwartz S,Trigwell CB.Feedback suppression of PI3Kα signaling in PTEN-mutated tumors is relieved by selective inhibition of PI3Kβ..Cancer Cell2015;27:109-22 PMCID:PMC4293347

[83] Kim J.mTOR as a central hub of nutrient signalling and cell growth..Nat Cell Biol2019;21:63-71

[84] Tian T,Zhang J.mTOR signaling in cancer and mTOR inhibitors in solid tumor targeting therapy..Int J Mol Sci2019;20:755 PMCID:PMC6387042

[85] Hua H,Zhang HY,Luo T.Targeting mTOR for cancer therapy..J Hematol Oncol2019;12:71 PMCID:PMC6612215

[86] Chen D,Zhang C.Dual PI3K/mTOR inhibitor BEZ235 as a promising therapeutic strategy against paclitaxel-resistant gastric cancer via targeting PI3K/Akt/mTOR pathway..Cell Death Dis2018;9:123 PMCID:PMC5833539

[87] Soares HP,Mellon M.Dual PI3K/mTOR inhibitors induce rapid overactivation of the MEK/ERK pathway in human pancreatic cancer cells through suppression of mTORC2..Mol Cancer Ther2015;14:1014-23 PMCID:PMC4394038

[88] Choi HJ,Park JY.A novel PI3K/mTOR dual inhibitor, CMG002, overcomes the chemoresistance in ovarian cancer..Gynecol Oncol2019;153:135-48

[89] Eswaran J,Kumar R.UnPAKing the class differences among p21-activated kinases..Trends Biochem Sci2008;33:394-403

[90] Kumar R.PAKs in human cancer progression: from inception to cancer therapeutic to future oncobiology..Adv Cancer Res2016;130:137-209

[91] Rane CK.P21 activated kinase signaling in cancer..Semin Cancer Biol2019;54:40-9

[92] Liu Y,Tian Y.The pak4 protein kinase plays a key role in cell survival and tumorigenesis in athymic mice..Mol Cancer Res2008;6:1215-24 PMCID:PMC2822623

[93] Zhou W,Lyle K.PAK1 mediates pancreatic cancer cell migration and resistance to MET inhibition..J Pathol2014;234:502-13 PMCID:PMC4380185

[94] Thillai K,Sarker D.Deciphering the link between PI3K and PAK: an opportunity to target key pathways in pancreatic cancer?.Oncotarget2017;8:14173-91 PMCID:PMC5355171

[95] Chen S,Dovirak O.Copy number alterations in pancreatic cancer identify recurrent PAK4 amplification..Cancer Biol Ther2008;7:1793-802 PMCID:PMC7323936

[96] Dart AE,Court W.PAK4 promotes kinase-independent stabilization of RhoU to modulate cell adhesion..J Cell Biol2015;211:863-79 PMCID:PMC4657161

[97] Kimmelman AC,Aguirre AJ.Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer..Proc Natl Acad Sci U S A2008;105:19372-7 PMCID:PMC2614768

[98] Mahlamäki EH,Monni O,Hautaniemi S.High-resolution genomic and expression profiling reveals 105 putative amplification target genes in pancreatic cancer..Neoplasia2004;6:432-9 PMCID:PMC1550328

[99] Begum A,Kozaki K.Identification of PAK4 as a putative target gene for amplification within 19q13.12-q13.2 in oral squamous-cell carcinoma..Cancer Sci2009;100:1908-16

[100] Davis SJ,Pearson RB,Gorringe KL.Functional analysis of genes in regions commonly amplified in high-grade serous and endometrioid ovarian cancer..Clin Cancer Res2013;19:1411-21

[101] Liu Y,Cui X.The protein kinase Pak4 disrupts mammary acinar architecture and promotes mammary tumorigenesis..Oncogene2010;29:5883-94 PMCID:PMC2974003

[102] He LF,Chen M.Activated-PAK4 predicts worse prognosis in breast cancer and promotes tumorigenesis through activation of PI3K/AKT signaling..Oncotarget2017;8:17573-85 PMCID:PMC5392270

[103] Bi Y,Le J.Study on the expression of PAK4 and P54 protein in breast cancer..World J Surg Oncol2016;14:160 PMCID:PMC4906770

[104] Minden A.The pak4 protein kinase in breast cancer..ISRN Oncol2012;2012:694201 PMCID:PMC3543797

[105] Zhuang T,Li Z.p21-activated kinase group II small compound inhibitor GNE-2861 perturbs estrogen receptor alpha signaling and restores tamoxifen-sensitivity in breast cancer cells..Oncotarget2015;6:43853-68 PMCID:PMC4791272

[106] Abo A,Cammarano MS.PAK4, a novel effector for Cdc42Hs, is implicated in the reorganization of the actin cytoskeleton and in the formation of filopodia..EMBO J1998;17:6527-40 PMCID:PMC1171000

[107] Li X.PAK4 functions in tumor necrosis factor (TNF) alpha-induced survival pathways by facilitating TRADD binding to the TNF receptor..J Biol Chem2005;280:41192-200

[108] Gnesutta N.Death receptor-induced activation of initiator caspase 8 is antagonized by serine/threonine kinase PAK4..Mol Cell Biol2003;23:7838-48 PMCID:PMC207651

[109] Gnesutta N,Minden A.The serine/threonine kinase PAK4 prevents caspase activation and protects cells from apoptosis..J Biol Chem2001;276:14414-9

[110] Murray BW,Piraino J.Small-molecule p21-activated kinase inhibitor PF-3758309 is a potent inhibitor of oncogenic signaling and tumor growth..Proc Natl Acad Sci U S A2010;107:9446-51 PMCID:PMC2889050

[111] Staben ST,Lyle K.Back pocket flexibility provides group II p21-activated kinase (PAK) selectivity for type I 1/2 kinase inhibitors..J Med Chem2014;57:1033-45

[112] Yeo D,Beutler JA.Glaucarubinone and gemcitabine synergistically reduce pancreatic cancer growth via down-regulation of P21-activated kinases..Cancer Lett2014;346:264-72 PMCID:PMC7681251

[113] Ryu BJ,Min B.Discovery and the structural basis of a novel p21-activated kinase 4 inhibitor..Cancer Lett2014;349:45-50

[114] Rane C,Baloglu E.A novel orally bioavailable compound KPT-9274 inhibits PAK4, and blocks triple negative breast cancer tumor growth..Sci Rep2017;7:42555 PMCID:PMC5309789

[115] Abu Aboud O,Senapedis W,Argueta C.Dual and specific inhibition of NAMPT and PAK4 By KPT-9274 decreases kidney cancer growth..Mol Cancer Ther2016;15:2119-29 PMCID:PMC5010932

[116] Aboukameel A,Senapedis W.Novel p21-activated kinase 4 (PAK4) allosteric modulators overcome drug resistance and stemness in pancreatic ductal adenocarcinoma..Mol Cancer Ther2017;16:76-87 PMCID:PMC5221563

[117] Fulciniti M,Senapedis W.Functional role and therapeutic targeting of p21-activated kinase 4 in multiple myeloma..Blood2017;129:2233-45 PMCID:PMC5399480

[118] Mohammad RM,Muqbil I.Targeting Rho GTPase effector p21 activated kinase 4 (PAK4) suppresses p-Bad-microRNA drug resistance axis leading to inhibition of pancreatic ductal adenocarcinoma proliferation..Small GTPases2019;10:367-77 PMCID:PMC6748371

[119] Takao S,Madan V.Targeting the vulnerability to NAD⁺ depletion in B-cell acute lymphoblastic leukemia..Leukemia2018;32:616-25

[120] Yoshino J,Imai SI.NAD⁺ intermediates: the biology and therapeutic potential of NMN and NR..Cell Metab2018;27:513-28 PMCID:PMC5842119

[121] Cordover E,Patel C.KPT-9274, an inhibitor of PAK4 and NAMPT, leads to downregulation of mTORC2 in triple negative breast cancer cells..Chem Res Toxicol2020;33:482-91

[122] Rane CK,Cai L,Baloglu E.Decrypting the PAK4 transcriptome profile in mammary tumor forming cells using next generation sequencing..Genomics2017;248-56

[123] Wintheiser GA.Physiology, tyrosine kinase receptors. In StatPearls.2020;Treasure Island (FL)StatPearls Publishing

[124] Yamaoka T,Ando K,Ohmori T.Receptor tyrosine kinase-targeted cancer therapy..Int J Mol Sci2018;19:3491 PMCID:PMC6274851